FIELD: pharmaceutics.
SUBSTANCE: invention relates to compounds of formula I, having inhibitory activity on BACE1 and/or BACE2, pharmaceutical compositions based thereon and method for use thereof. In general formula I R1 represents a halogen, R2 is selected from a group consisting of i) C1-6-alkyl and ii) a halogen-C-1-6-alkyl; R3 is selected from group consisting of i) hydrogen and ii) C1-6-alkyl; R4 is selected from a group consisting of i) hydrogen and ii) C1-6-alkyl; R5 is a 5-6-member heteroaryl with 1-2 nitrogen atoms, substituted with halogen, R6 represents hydrogen; R7 represents hydrogen; R8 represents hydrogen; R9 represents hydrogen; or R6 and R8 together form a 5-6-member heterocyclyl containing 1 oxygen atom, X is selected from a group consisting of i) -S and ii) -SO2.
EFFECT: compounds are useful in therapeutic and/or preventive treatment, for example, Alzheimer's disease and diabetes type 2.
29 cl, 8 tbl, 14 ex
Title | Year | Author | Number |
---|---|---|---|
2, 5, 6, 7-TETRAHYDRO-[1, 4]OXAZEPIN-3-YLAMINES OR 2, 3, 6, 7-TETRAHYDRO-[1, 4]OXAZEPIN-5-YLAMINES | 2011 |
|
RU2570796C2 |
PIPERAZINO[1,2-A]INDOLE-1-ONES AND [1,4] DIAZEPTINO[1,2-A]INDOLE-1-ONE | 2014 |
|
RU2628126C2 |
N-[3-(5-AMINO-3,3A,7,7A-TETRAHYDRO-1H-2,4-DIOXA-6-AZA-INDEN-7-YL)-PHENYL]-AMIDES AS INHIBITORS OF BACE1 AND(OR) BACE2 | 2012 |
|
RU2597308C2 |
AMINOMETHYL QUINOLONES USEFUL IFOR TREATMENT OF JNK-MEDIATED DISORDER | 2012 |
|
RU2629111C2 |
DOUBLE NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | 2005 |
|
RU2374229C2 |
PIPERIDINE DERIVATIVES | 2011 |
|
RU2554353C2 |
SULTAM DERIVATIVES | 2010 |
|
RU2565752C2 |
TRIAZOLE DERIVATIVES AS GABA RECEPTOR LIGANDS | 2011 |
|
RU2582337C2 |
SUBSTITUTED BENZAMIDE DERIVATIVES | 2010 |
|
RU2595902C2 |
PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | 2006 |
|
RU2411237C2 |
Authors
Dates
2016-10-27—Published
2012-02-28—Filed